Recently, a melittin-based lipid nanoparticle vaccine targeted the lymph node due to its size and particle charge32 and stimulated both CD4+ and CD8+ T cells by lysing tumor cells and activating myeloid cells tumor cell lysis and myeloid cell activation. This evidence concerns the gene CD4 and neoplasm.